Emergent BioSolutions Inc. company info

CIK 1367644
IRS Number 141902018
State of incorporation DE
Business address 400 PROFESSIONAL DR, SUITE 400
Mail address 400 PROFESSIONAL DR, SUITE 400

Short summary

Emergent BioSolutions Inc. is a Maryland company, with head office located at 400 Professional Dr, Suite 400 Gaithersburg, Maryland 20879. The company achieved a record breaking net income in 2015 - 62.87 million USD. In 2016 the company owned a total of 970.48 million USD worth of assets, including 509.74 million USD worth of current assets. 2015 was the year when the company amassed the most assets. The company net sales last year amounted to 488.78 million USD. The company allocated 108.29 million USD of its income to research and development.

Emergent BioSolutions Inc. Income Statement

Name [in Millions USD]200820092010201120122013201420152016Trends
Revenue, Net 234.79286.17273.38281.89312.75450.14489.33488.78
Selling, General and Administrative Expense 73.7976.2174.2876.0287.88122.84148.46143.69
Research and development 74.5989.30124.83120.23119.93150.83119.19108.29
Operating Income (Loss) 40.1573.5632.1029.9742.8089.19141.51105.52
Interest expense 0.01000.0108.246.527.62
Other Nonoperating Income (Expense) -0.05-1.02-0.261.970.432.930.150.26
Income Tax Expense (Benefit) 14.9726.1815.8313.9213.1129.9344.3036.70
Net income 31.1451.7023.0223.5231.1436.7462.8751.78

Emergent BioSolutions Inc. Balance Sheet

Name [in Millions USD]200820092010201120122013201420152016Trends
Cash and cash equivalents 91.47102.19122.09161.84156.24168.13214.84333.40315.63
Accounts Receivable, Net, Current 47.2646.8254.3778.2799.7266.75102.51
Inventories 17.2616.0118.5866.0384.7196.6770.53
Deferred income taxes 7.080.641.2601.4800
Property, Plant and Equipment, Gross 241.43284.71321.61393.41469.16507.62
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment 32.4642.9457.3779.43110.13127.38
Goodwill 5.035.505.5047.1952.5954.9041.00
Intangible Assets, Net (Excluding Goodwill) 066.6862.1152.6530.76
Other Assets, Noncurrent 0.710.710.568.777.251.853.72
Total assets 493.98527.14555.61837.25943.321,056.47970.48
Current assets 223.84243.22248.16345.45435.49528.05509.74
Accounts payable 32.1823.3025.7136.9741.8258.9729.60
Taxes Payable, Current 00.120
Total current liabilities 72.5044.4748.7876.4386.96103.8672.93
Long-term Debt, Excluding Current Maturities 29.0758.1456.07251253247.39248.69
Long-term Debt 62.2062.7762
Deferred Revenue, Noncurrent 2.9501.636.088.4117.09
Deferred income taxes 00
Total liabilities 112.75104.62106.53349.48381.07383.79349.88
Common Stock, Value, Issued
Retained Earnings (Accumulated Deficit) 166.66197.67222.81236.32280.85344.18269.58
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.77-3.25-3.51-3.25-3.66-3.08-3.52

Emergent BioSolutions Inc. Cash Flow

Name [in Millions USD]200820092010201120122013201420152016Trends
Net income 31.1451.7023.0223.5231.1436.7462.8751.78
Amortization of Intangible Assets 1.956.997.386.89
Depreciation and amortization 5.005.999.3611.2018.9622.3424.5028.02
Deferred Income Tax Expense (Benefit) 5.759.2320.193.3813.8616.493.465.19
Accounts receivable 30.02-19.0934.8721.89-35.46-21.4164.3522.45
Inventories -6.21-0.801.940.50-0.52-4.2311.269.03
Accounts payable -1.553.392.510.27-0.55-9.284.75-14.79
Deferred revenue -0.01-0.84-10.860.450.032.853.474.60
Net Cash Provided by (Used in) Operating Activities 29.8798.9312.1939.6496.97112.32
Payments to Acquire Property, Plant, and Equipment 33.2922.1054.0353.8542.0230.6744.8176.26
Payments to Acquire Businesses, Net of Cash Acquired 017.870025.87179.380.650
Net Cash Provided by (Used in) Investing Activities -33.29-23.46-53.96-40.11-67.89-210.05
Net Cash Provided by (Used in) Investing Activities, Continuing Operations -67.89-210.05-45.46-76.26
Proceeds from Issuance of Long-term Debt 120
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures 16.0022.9710.3116.6726.5943.7534.47
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures 16.0022.9710.3116.6726.5943.7534.47
Payments for Repurchase of Common Stock 005.910.210.200.100
Net Cash Provided by (Used in) Financing Activities 14.84-8.4514.25-1.778.61198.87
Cash and Cash Equivalents, Period Increase (Decrease) 11.4566.10-25.12-2.2437.67101.1632.30-41.28